IN THIS ISSUE of the Archives, O'Brien and colleagues1 use the increasingly popular technique of decision analysis to conclude that from an economic standpoint, it is much less costly to treat uncomplicated duodenal ulcer disease associated with Helicobacter pylori by eradicating the infection rather than by continuing the time-honored practice of intermittent or continuous maintenance therapy with H2 receptor antagonists. Their article underscores many important clinical and economic issues regarding peptic ulcers and H pylori, yet leaves many issues unanswered.
See also page 1958
Helicobacter pylori was first described in 1983 by Warren2 and Marshall3 in association with active chronic gastritis. Shortly thereafter, H pylon's association with duodenal and gastric ulcers was noted, leading to an incredible proliferation of interest as manifested by the dominance of H pylori in the ulcer literature for the past decade.4 Eradication of H pylori has been unequivocally proved to
Fennerty MB. 'Cure' of Helicobacter pylori: Clinically Indicated and Economically Wise! Arch Intern Med. 1995;155(18):1929–1931. doi:10.1001/archinte.1995.00430180017003
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: